Restless Leg Syndrome: Why Your Legs Won't Let You Sleep

What Is Restless Leg Syndrome?

Restless Legs Syndrome (RLS) — also called Willis-Ekbom disease — is a neurological sensorimotor disorder defined by an irresistible urge to move the legs, typically accompanied by uncomfortable sensations. Diagnosing RLS requires meeting all five essential criteria established by the International Restless Legs Syndrome Study Group (IRLSSG).

Symptoms worsen during rest or inactivity, improve with movement, and are worst in the evening and at night. This circadian pattern of symptom worsening is precisely what makes RLS such an effective sleep disruptor. Many cases of chronic insomnia have an underlying RLS component that goes unrecognized. For a broader look at insomnia, see the insomnia in older adults guide.

Prevalence estimates vary, but a large systematic review found the global adult prevalence of RLS to be approximately 7%, with clinically significant RLS — symptoms occurring at least weekly with functional impairment — affecting roughly 2–3% of adults. Women are affected at nearly twice the rate of men.

The Brain Iron–Dopamine Connection

RLS is not a leg problem. It is a brain problem. Specifically, it is a neurological disorder in which brain iron deficiency disrupts dopaminergic signaling pathways.

Iron is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis. Without adequate iron, dopamine production is impaired — and the neural circuits responsible for sensorimotor control of the legs cannot function properly.

In 2001, Allen and colleagues used MRI to directly measure brain iron concentrations in RLS patients, finding significantly lower iron levels in the substantia nigra — the brain's primary dopamine production center. This finding has been replicated repeatedly, and altered brain iron homeostasis is now recognized as one of the fundamental pathological factors in RLS.

The key clinical implication involves ferritin thresholds. In sleep medicine, serum ferritin below 75 μg/L — well above the standard anemia cutoff of ~20 μg/L — is considered potentially indicative of impaired brain iron metabolism. Iron supplementation at this threshold can meaningfully improve RLS symptoms. For more on minerals that affect sleep quality, see the magnesium and sleep guide.

Primary vs. Secondary RLS: Understanding the Causes

RLS is classified as either primary (idiopathic) or secondary. Primary RLS occurs without an identifiable underlying cause and has a strong genetic component — first-degree relatives of RLS patients have a 3–5 times higher risk. Secondary RLS has a specific medical or pharmacological trigger.

The most common causes of secondary RLS include:

• Iron deficiency and anemia. The most common secondary cause. Iron deficiency can stem from poor diet, gastrointestinal bleeding, frequent blood donation, or malabsorption disorders.
• Pregnancy. Particularly in the third trimester. Increased demands for iron and folate, rising estrogen, and changes in dopamine pathways all contribute. Most cases resolve within weeks of delivery. For more on pregnancy sleep challenges, see the pregnancy and postpartum insomnia guide.
• Chronic kidney disease (CKD). RLS prevalence in CKD patients is 3–4 times that of the general population. Uremic toxins disrupt dopamine pathways, and impaired kidney function compromises iron metabolism. Hemodialysis patients are disproportionately affected.
• Medications. Several drug classes can trigger or worsen RLS. Key offenders include antihistamines (diphenhydramine), certain antidepressants (tricyclics, SSRIs, SNRIs), dopamine-blocking antiemetics (metoclopramide), and lithium. For a detailed look at medication effects on sleep, see the medication-induced insomnia guide.
• Diabetic neuropathy. Patients with diabetic peripheral neuropathy have elevated rates of RLS, and overlapping sensory symptoms can complicate diagnosis.

How Does RLS Wreck Your Sleep?

RLS disrupts sleep in multiple, compounding ways. A 2023 systematic review and meta-analysis of polysomnographic findings in RLS patients found significantly elevated wake after sleep onset (WASO), stage shift frequency, N1 percentage, REM latency, and arousal index compared to healthy controls.

RLS is also closely associated with Periodic Limb Movements during Sleep (PLMS) — repetitive, involuntary leg jerking or kicking that occurs during sleep. PLMS occurs in up to 90% of RLS patients. Each PLMS episode triggers a microarousal from sleep, producing sleep fragmentation even when the patient is unaware of awakening. The result is non-restorative sleep despite adequate time in bed.

The consequences of chronic sleep fragmentation are broad: daytime fatigue, impaired concentration, memory deficits, and mood disturbances. RLS severity shows a dose-response relationship with subjective sleep quality and quality-of-life impairment — the worse the RLS, the greater the sleep and functional consequences. For more on what sleep fragmentation does to your health, see the exercise timing and sleep guide.

Evidence-Based Treatments: What the 2025 AASM Guidelines Say

In 2025, the AASM published a major update to its clinical practice guidelines for RLS — representing a significant paradigm shift away from dopamine agonists toward gabapentinoids and iron therapy as the new standard of care.

1. Iron evaluation and supplementation. The 2025 guideline strongly recommends iron evaluation in all RLS patients. If ferritin is below 75 μg/L, oral or intravenous iron supplementation is initiated. Intravenous ferric carboxymaltose received a strong recommendation rating. Iron therapy addresses the root cause and should be the first treatment attempted.
2. Gabapentinoids (first-line pharmacotherapy). Gabapentin enacarbil, gabapentin, and pregabalin are now recommended as first-line pharmacotherapy for most RLS patients, receiving strong recommendations with moderate certainty of evidence. Crucially, gabapentinoids do not carry the augmentation risk associated with dopamine agonists.
3. Dopamine agonists (no longer first-line). Ropinirole, pramipexole, and rotigotine patches are no longer recommended as standard first-line treatments. Long-term use carries significant augmentation risk — a paradoxical worsening in which symptoms spread to earlier in the day, become more intense, and affect more body areas. They may still be considered in specific cases unresponsive to other treatments, but require close monitoring.
4. Low-dose opioids (severe, refractory cases). Low-dose extended-release opioids (e.g., oxycodone) may be used in severe, refractory RLS that does not respond to other treatments. They require close specialist supervision due to dependency and adverse effect risks.

For secondary RLS, treating the underlying cause — iron deficiency, CKD, or discontinuing offending medications — is often sufficient to resolve symptoms. Switching from a dopamine-blocking antiemetic or antihistamine to an alternative is sometimes all that is needed.

Non-Pharmacological Strategies for RLS

For mild-to-moderate RLS, or for patients who prefer to minimize medications, non-pharmacological approaches can provide meaningful symptom relief. The following strategies have clinical evidence supporting their use.

1. Pneumatic compression devices. In a randomized, double-blinded, sham-controlled trial, using a pneumatic compression device for at least 1 hour before bedtime produced clinically significant RLS symptom improvement versus the sham device. Compression stockings may also provide benefit in some patients.
2. Regular moderate aerobic exercise. Moderate-intensity aerobic exercise significantly reduces RLS severity in controlled studies. The important caveat is timing: vigorous exercise close to bedtime can worsen RLS symptoms. Evening exercise should end 3–4 hours before bed, or be shifted to morning or afternoon. For more on how exercise timing affects sleep quality overall, see the exercise timing and sleep guide.
3. Hot or cold therapy and massage. Hot baths, cold packs, leg massage, and stretching provide temporary symptom relief for many patients. Effects are short-lasting, but incorporating these into a pre-sleep routine can ease the transition to sleep. Individual responses to hot versus cold vary, making personal experimentation valuable.
4. Avoiding RLS triggers. Caffeine, alcohol, antihistamines (including OTC sleep aids), and certain antidepressants are among the most common RLS exacerbators. Eliminating these triggers can sometimes be as impactful as adding a medication. Reviewing all medications with your doctor for possible RLS contributions is worthwhile.
5. Sleep hygiene optimization. Maintaining a consistent sleep schedule, keeping the bedroom cool, and limiting light exposure before bed all help reduce RLS-related sleep problems. A structured pre-sleep relaxation routine can lower the nervous system's arousal threshold, making RLS symptoms less likely to escalate at bedtime.

Frequently Asked Questions

References

1. Allen, R. P., et al. (2001). MRI measurement of iron in the basal ganglia in RLS. Neurology, 56(2), 263-265.
2. Allen, R. P., et al. (2014). Restless legs syndrome diagnostic criteria: updated IRLSSG consensus. Sleep Medicine, 15(8), 860-873.
3. Trenkwalder, C., et al. (2018). Restless legs syndrome: pathophysiology and treatment. The Lancet Neurology, 17(11), 1004-1014.
4. Silber, M. H., et al. (2021). Management of restless legs syndrome: an updated algorithm. Mayo Clinic Proceedings, 96(7), 1921-1937.
5. Winkelman, J. W., et al. (2016). Practice guideline: treatment of RLS in adults. Neurology, 87(24), 2585-2593.
6. Manconi, M., et al. (2004). Restless legs syndrome and pregnancy. J Neurol Neurosurg Psychiatry, 75(7), 1034-1039.
7. Lettieri, C. J., & Eliasson, A. H. (2009). Pneumatic compression devices for RLS. Sleep Medicine, 10(4), 402-406.
8. Aukerman, M. M., et al. (2006). Exercise and RLS: a randomized controlled trial. JABFM, 19(5), 487-493.